Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of hepatitis-C-focused biotechnology company Achillion Pharmaceuticals (NASDAQ: ACHN ) dropped as much as 12% following the release of interim results for a phase 2a trial with its lead drug candidate, ACH-3102.
So what: The interim data released today was based on just eight patients with genotype 1b. Based on the data, ACH-3102, which is given with ribavirin, has been well tolerated in all patients. Three of the patients have completed 12 weeks of treatment, with five others having completed four weeks. The two primary endpoints, in addition to safety goals, are a rapid virologic response, or RVR, as well as an end of treatment response, or ETR. All three patients who have completed the 12 week treatment demonstrated the expected ETR; however, only four of five patients after four weeks met the RVR endpoint.
Now what: Given that Gilead Sciences' (NASDAQ: GILD ) sofosbuvir has been nearly perfect by itself and in combination with other drugs --including its own GS-5885 and Bristol-Myers Squibb's (NYSE: BMY ) daclatasvir -- Achillion's ACH-3102 practically needs to have perfect marks across the board to get investors excited. Today's data is incomplete and just a snippet of what to expect, but even that one patient of five not to meet the RVR endpoint is enough to concern investors. I remain steadfast in my opinion that Gilead is the way to play the hepatitis-C sector and all other competitors are merely second fiddle at best.
Your ticket to a 98% success rate
Gilead Sciences has been a longtime pick of Motley Fool superinvestor David Gardner, and has soared 110% since he recommended it in September 2010. David specializes in identifying game-changing companies like this long before others are keen to their disruptive potential and helping like-minded investors profit while Wall Street catches up. I invite you to learn more about how he picks his winners with a free, personal tour of his flagship service: Supernova. Inside you'll discover the science behind his market-trouncing returns. Just click here now for instant access.